Pegaptanib for Neovascular Age-Related Macular Degeneration

Pegaptanib for neovascular age-related macular degeneration.

(1) Neovascular (wet) age-related macular degeneration (AMD) results from the growth of abnormal blood vessels under the retina (choroidal neovascularization). Sudden and permanent vision loss occurs as these vessels grow, leak, bleed, and scar. (2) A human protein, vascular endothelial growth factor (VEGF), is implicated in the development of wet AMD. Pegaptanib attaches to VEGF and blocks its...

Pegaptanib for Neovascular Age-Related Macular Degeneration

Disclaimer/Complaints regulations If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: http://uba.uva.nl/en/contact, or a letter to: Library of ...

Neovascular Age - Related Macular Degeneration

Pegaptanib sodium for neovascular age-related macular degeneration: clinical experience in the UK

The pathogenesis of age-related macular degeneration (AMD) is unclear, but it can take either a neovascular/exudative/wet form, characterized by choroidal neovascularization (CNV), or a dry form. No treatments are available for the dry form, but there are a number of pharmacological interventions that inhibit vascular endothelial growth factor (VEGF), which is central to the pathogenesis of CNV...

Measurement of Choroidal Neovascular Area in Age-Related Macular Degeneration using Modified Otsu’s Thresholding Method

Introduction: Age-related Macular Degeneration (AMD) is one of the most important causes of irreversible  blindness in the developed world and  prevents the affected  person from  performing simple tasks such  as  reading,  driving  and  facial  recognition.  In  the  AMD,  new  blood  vessels  grow  underneath  the  retina  in  a  process  called  choroidal  neovascularisation  (CNV).  There  ...